Centiva Capital’s Soleno Therapeutics SLNO Stock Holding History

Centiva Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-101,234	Closed	-$3.39M	–	2178
2026 Q1	$3.39M	Sell	101,234 -17,570	-15%	-$689K	0.03%	330
2025 Q4	$5.5M	Buy	+118,804	New	+$6.51M	0.04%	248
2025 Q3	–	Sell	-5,000	Closed	-$371K	–	1775
2025 Q2	$419K	Buy	5,000 +4,100	+456%	+$307K	0.01%	1040
2025 Q1	$64.3K	Buy	+900	New	+$43.8K	﹤0.01%	1429

Centiva Capital's SLNO Position: Q2 2026 in Review

Centiva Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 101,234 shares — an estimated $3.39M sold.

Centiva Capital first reported a position in SLNO in Q1 2025 and held it in 4 quarters. The position peaked at $5.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Centiva Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 101,234 Soleno Therapeutics shares in Q2 2026, an estimated $3.39M.
Centiva Capital first reported a position in Soleno Therapeutics in Q1 2025 and held it in 4 quarters.
Centiva Capital's Soleno Therapeutics position peaked at $5.5M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.